acetaminophen has been researched along with Fatty Liver, Nonalcoholic in 23 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The overuse of acetaminophen (APAP) may cause more severe hepatotoxicity in patients with non-alcoholic fatty liver disease (NAFLD)." | 8.31 | Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway. ( Fu, D; Hu, C; Huang, Y; Jiang, X; Li, Y; Wen, J; Wu, S; Xin, J; You, T, 2023) |
| "The degree of liver inflammation and hepatocellular necrosis were significantly higher in HFGD fed animals after acetaminophen administration." | 7.78 | Susceptibility of rat non-alcoholic fatty liver to the acute toxic effect of acetaminophen. ( Cervinková, Z; Haňáčková, L; Kučera, O; Lotková, H; Podhola, M; Roušar, T; Staňková, P, 2012) |
| ": The aim of the study was to evaluate UDP-glucuronyltransferase activity and the pharmacokinetics of a single oral dose of acetaminophen (APAP) in children with nonalcoholic fatty liver disease (NAFLD)." | 7.77 | Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. ( Barshop, NJ; Capparelli, EV; Lavine, JE; Schwimmer, JB; Sirlin, CB, 2011) |
| " Moreover, there is evidence that the maximum recommended dosage can induce hepatic cytolysis in some individuals." | 6.50 | Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. ( Fromenty, B; Michaut, A; Moreau, C; Robin, MA, 2014) |
| " The literature shows that excessive or long-term use of APAP can lead to increased cardiovascular dysfunction." | 5.91 | Caveolin-1 alleviates acetaminophen-induced vascular oxidative stress and inflammation in non-alcoholic fatty liver disease. ( Feng, X; Fu, D; Hu, C; Huang, Y; Jiang, X; Li, Y; Wen, J; Wu, S; Xin, J; You, T, 2023) |
| "Acetaminophen (APAP) is a common antipyretic and analgesic drug that can cause long-term liver damage after an overdose." | 5.91 | Caveolin-1 protects against liver damage exacerbated by acetaminophen in non-alcoholic fatty liver disease by inhibiting the ERK/HIF-1α pathway. ( Fu, D; Hu, C; Huang, Y; Jiang, X; Jin, L; Li, B; Li, Y; Wu, S; Xin, J; You, T, 2023) |
| "Acetaminophen (APAP) is a readily available and safe painkiller." | 5.46 | Fast food diet-induced non-alcoholic fatty liver disease exerts early protective effect against acetaminophen intoxication in mice. ( Choi, D; Kim, JY; Kim, TH; Koo, SH; Lee, JH, 2017) |
| "Obesity and nonalcoholic fatty liver disease (NAFLD) can increase susceptibility to hepatotoxicity induced by some xenobiotics including drugs, but the involved mechanisms are poorly understood." | 5.43 | A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen. ( Bucher, S; Fromenty, B; Gicquel, T; Jaeschke, H; Le Guillou, D; Martinais, S; McGill, MR; Michaut, A; Moreau, C; Morel, I; Robin, MA, 2016) |
| " Despite abundant experimental data showing that fatty liver is more susceptible to liver injury, drug-induced liver disease seems no more frequent in NAFLD patients, except, possibly, a higher incidence but not severity of acetaminophen hepatotoxicity." | 4.90 | The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. ( Pais, R; Ratziu, V; Rusu, E, 2014) |
| " This review summarises the evidence for potential therapeutic applications of non-immunosuppressive cyclophilin inhibitors, alone or in combination with other agents, in virus-induced liver diseases like hepatitis C, B or Delta, liver inflammation and fibrosis, acetaminophen-induced liver toxicity and hepatocellular carcinoma." | 4.90 | Cyclophilin inhibition as potential therapy for liver diseases. ( Naoumov, NV, 2014) |
| "The overuse of acetaminophen (APAP) may cause more severe hepatotoxicity in patients with non-alcoholic fatty liver disease (NAFLD)." | 4.31 | Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway. ( Fu, D; Hu, C; Huang, Y; Jiang, X; Li, Y; Wen, J; Wu, S; Xin, J; You, T, 2023) |
| " Inflammation and fibrosis were evaluated by transaminases, myeloperoxidase activity, hydroxyproline, and histological evaluation." | 4.12 | Chronic intermittent hypoxia promotes early intrahepatic endothelial impairment in rats with nonalcoholic fatty liver disease. ( Abrante, B; Abreu-González, P; de la Barreda, R; Díaz-Flores, F; González-Paredes, FJ; Hernández-Bustabad, A; Hernández-Guerra, M; Morales-Arraez, D; Quintero, E, 2022) |
| "The degree of liver inflammation and hepatocellular necrosis were significantly higher in HFGD fed animals after acetaminophen administration." | 3.78 | Susceptibility of rat non-alcoholic fatty liver to the acute toxic effect of acetaminophen. ( Cervinková, Z; Haňáčková, L; Kučera, O; Lotková, H; Podhola, M; Roušar, T; Staňková, P, 2012) |
| ": The aim of the study was to evaluate UDP-glucuronyltransferase activity and the pharmacokinetics of a single oral dose of acetaminophen (APAP) in children with nonalcoholic fatty liver disease (NAFLD)." | 3.77 | Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. ( Barshop, NJ; Capparelli, EV; Lavine, JE; Schwimmer, JB; Sirlin, CB, 2011) |
| "Non-alcoholic fatty liver disease (NAFLD) is a global condition characterized by an accumulation of lipids in the hepatocytes." | 2.72 | Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators. ( Arconzo, M; Moschetta, A; Piccinin, E, 2021) |
| " Moreover, there is evidence that the maximum recommended dosage can induce hepatic cytolysis in some individuals." | 2.50 | Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. ( Fromenty, B; Michaut, A; Moreau, C; Robin, MA, 2014) |
| " The literature shows that excessive or long-term use of APAP can lead to increased cardiovascular dysfunction." | 1.91 | Caveolin-1 alleviates acetaminophen-induced vascular oxidative stress and inflammation in non-alcoholic fatty liver disease. ( Feng, X; Fu, D; Hu, C; Huang, Y; Jiang, X; Li, Y; Wen, J; Wu, S; Xin, J; You, T, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease and its influence on drug-induced liver injury (DILI) is not fully understood." | 1.91 | Absence of Increased Susceptibility to Acetaminophen-Induced Liver Injury in a Diet-Induced NAFLD Mouse Model. ( Clayton, NP; Cortes, RA; Izawa, T; Pandiri, AR; Sills, RC; Travlos, GS, 2023) |
| "Acetaminophen (APAP) is a common antipyretic and analgesic drug that can cause long-term liver damage after an overdose." | 1.91 | Caveolin-1 protects against liver damage exacerbated by acetaminophen in non-alcoholic fatty liver disease by inhibiting the ERK/HIF-1α pathway. ( Fu, D; Hu, C; Huang, Y; Jiang, X; Jin, L; Li, B; Li, Y; Wu, S; Xin, J; You, T, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) prevails in obesity and is linked to several health complications including dyslipidemia and atherosclerosis." | 1.51 | The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis. ( Aldow, M; Barbier, O; Beaulieu, MJ; Camiré, É; Caron, A; Festuccia, WT; Gélinas, Y; Guénard, F; Joubert, P; Jubinville, É; Kaci, I; Karvellas, CJ; Labbé, SM; Lamothe, J; Laplante, M; Marette, A; Mitchell, PL; Morissette, MC; Mouchiroud, M; Rose, CF; Roy, C; Trottier, J; Turcotte, L; Varin, TV, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease which affects millions of people worldwide." | 1.51 | Acetaminophen aggravates fat accumulation in NAFLD by inhibiting autophagy via the AMPK/mTOR pathway. ( Han, B; Hu, C; Shi, C; Xue, W; Yang, F; Yin, Y, 2019) |
| "Acetaminophen (APAP) is a readily available and safe painkiller." | 1.46 | Fast food diet-induced non-alcoholic fatty liver disease exerts early protective effect against acetaminophen intoxication in mice. ( Choi, D; Kim, JY; Kim, TH; Koo, SH; Lee, JH, 2017) |
| "Obesity and nonalcoholic fatty liver disease (NAFLD) can increase susceptibility to hepatotoxicity induced by some xenobiotics including drugs, but the involved mechanisms are poorly understood." | 1.43 | A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen. ( Bucher, S; Fromenty, B; Gicquel, T; Jaeschke, H; Le Guillou, D; Martinais, S; McGill, MR; Michaut, A; Moreau, C; Morel, I; Robin, MA, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, representing a spectrum of liver pathologies that include simple hepatic steatosis and the more advanced nonalcoholic steatohepatitis (NASH)." | 1.42 | Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis. ( A-Kader, HH; Bataille, AM; Campion, SN; Canet, MJ; Cherrington, NJ; Erickson, RP; Ferreira, DW; Hardwick, RN; Manautou, JE; Merrell, MD; Xanthakos, SA, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis." | 1.39 | Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. ( Cherrington, NJ; Ferreira, DW; Hardwick, RN; Lake, AD; Lu, Z; Manautou, JE; More, VR; Slitt, AL, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 8 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández-Bustabad, A | 1 |
| Morales-Arraez, D | 1 |
| González-Paredes, FJ | 1 |
| Abrante, B | 1 |
| Díaz-Flores, F | 1 |
| Abreu-González, P | 1 |
| de la Barreda, R | 1 |
| Quintero, E | 1 |
| Hernández-Guerra, M | 1 |
| Fu, D | 3 |
| Wu, S | 3 |
| Jiang, X | 3 |
| You, T | 3 |
| Li, Y | 3 |
| Xin, J | 3 |
| Feng, X | 1 |
| Wen, J | 2 |
| Huang, Y | 3 |
| Hu, C | 4 |
| Izawa, T | 1 |
| Travlos, GS | 1 |
| Cortes, RA | 1 |
| Clayton, NP | 1 |
| Sills, RC | 1 |
| Pandiri, AR | 1 |
| Li, B | 1 |
| Jin, L | 1 |
| Mouchiroud, M | 1 |
| Camiré, É | 1 |
| Aldow, M | 1 |
| Caron, A | 1 |
| Jubinville, É | 1 |
| Turcotte, L | 1 |
| Kaci, I | 1 |
| Beaulieu, MJ | 1 |
| Roy, C | 1 |
| Labbé, SM | 1 |
| Varin, TV | 1 |
| Gélinas, Y | 1 |
| Lamothe, J | 1 |
| Trottier, J | 1 |
| Mitchell, PL | 1 |
| Guénard, F | 1 |
| Festuccia, WT | 1 |
| Joubert, P | 1 |
| Rose, CF | 1 |
| Karvellas, CJ | 1 |
| Barbier, O | 1 |
| Morissette, MC | 1 |
| Marette, A | 1 |
| Laplante, M | 1 |
| García-Román, R | 1 |
| Francés, R | 1 |
| Arconzo, M | 1 |
| Piccinin, E | 1 |
| Moschetta, A | 1 |
| Cheng, D | 1 |
| Gong, X | 1 |
| Wu, Q | 1 |
| Yuan, J | 1 |
| Lv, Y | 1 |
| Yuan, L | 1 |
| Zhang, X | 1 |
| Kim, TH | 1 |
| Choi, D | 1 |
| Kim, JY | 1 |
| Lee, JH | 1 |
| Koo, SH | 1 |
| Chao, X | 1 |
| Wang, H | 1 |
| Jaeschke, H | 2 |
| Ding, WX | 1 |
| Shi, C | 1 |
| Xue, W | 1 |
| Han, B | 1 |
| Yang, F | 1 |
| Yin, Y | 1 |
| Chen, Y | 1 |
| Dong, H | 1 |
| Thompson, DC | 1 |
| Shertzer, HG | 1 |
| Nebert, DW | 1 |
| Vasiliou, V | 1 |
| Pais, R | 1 |
| Rusu, E | 1 |
| Ratziu, V | 1 |
| Michaut, A | 2 |
| Moreau, C | 2 |
| Robin, MA | 2 |
| Fromenty, B | 2 |
| Naoumov, NV | 1 |
| Canet, MJ | 1 |
| Merrell, MD | 1 |
| Hardwick, RN | 2 |
| Bataille, AM | 1 |
| Campion, SN | 1 |
| Ferreira, DW | 2 |
| Xanthakos, SA | 1 |
| Manautou, JE | 2 |
| A-Kader, HH | 1 |
| Erickson, RP | 1 |
| Cherrington, NJ | 2 |
| Szabo, G | 1 |
| Petrasek, J | 1 |
| Le Guillou, D | 1 |
| Bucher, S | 1 |
| McGill, MR | 1 |
| Martinais, S | 1 |
| Gicquel, T | 1 |
| Morel, I | 1 |
| Barshop, NJ | 1 |
| Capparelli, EV | 1 |
| Sirlin, CB | 1 |
| Schwimmer, JB | 1 |
| Lavine, JE | 1 |
| Kučera, O | 1 |
| Roušar, T | 1 |
| Staňková, P | 1 |
| Haňáčková, L | 1 |
| Lotková, H | 1 |
| Podhola, M | 1 |
| Cervinková, Z | 1 |
| Kubes, P | 1 |
| Mehal, WZ | 1 |
| More, VR | 1 |
| Lake, AD | 1 |
| Lu, Z | 1 |
| Slitt, AL | 1 |
9 reviews available for acetaminophen and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Acetaminophen-Induced Liver Damage in Hepatic Steatosis.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Glutathione; Hepatocytes; Humans; No | 2020 |
Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Dose-Response Relationship, Drug; Humans; Liver Fa | 2021 |
Role and mechanisms of autophagy in acetaminophen-induced liver injury.
Topics: Acetaminophen; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Disease Models, Animal; H | 2018 |
Glutathione defense mechanism in liver injury: insights from animal models.
Topics: Acetaminophen; Animals; Disease Models, Animal; Fatty Liver; Gene Deletion; Glutamate-Cysteine Ligas | 2013 |
The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease.
Topics: Acetaminophen; Anesthetics; Animals; Chemical and Drug Induced Liver Injury; Fatty Liver; Female; He | 2014 |
Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease.
Topics: Acetaminophen; Animals; Benzoquinones; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3 | 2014 |
Cyclophilin inhibition as potential therapy for liver diseases.
Topics: Acetaminophen; Animals; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Cyclophil | 2014 |
Inflammasome activation and function in liver disease.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Disease Prog | 2015 |
Sterile inflammation in the liver.
Topics: Acetaminophen; Adenosine Triphosphate; Caspase 1; Chemical and Drug Induced Liver Injury; Chemotaxis | 2012 |
14 other studies available for acetaminophen and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Chronic intermittent hypoxia promotes early intrahepatic endothelial impairment in rats with nonalcoholic fatty liver disease.
Topics: Acetaminophen; Acetylcholine; Animals; Hydroxyproline; Hypoxia; Inflammation; Intercellular Adhesion | 2022 |
Caveolin-1 alleviates acetaminophen-induced vascular oxidative stress and inflammation in non-alcoholic fatty liver disease.
Topics: Acetaminophen; Animals; Caveolin 1; Chemical and Drug Induced Liver Injury; Inflammation; Liver; Mal | 2023 |
Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway.
Topics: Acetaminophen; Animals; Carrier Proteins; Caveolin 1; Chemical and Drug Induced Liver Injury; Inflam | 2023 |
Absence of Increased Susceptibility to Acetaminophen-Induced Liver Injury in a Diet-Induced NAFLD Mouse Model.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Inju | 2023 |
Caveolin-1 protects against liver damage exacerbated by acetaminophen in non-alcoholic fatty liver disease by inhibiting the ERK/HIF-1α pathway.
Topics: Acetaminophen; Animals; Caveolin 1; Chemical and Drug Induced Liver Injury; Hypoxia-Inducible Factor | 2023 |
The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis.
Topics: Acetaminophen; Adult; Animals; Bile Acids and Salts; Biomarkers; Chemical and Drug Induced Liver Inj | 2019 |
High-Selectivity Fluorescent Reporter toward Peroxynitrite in a Coexisting Nonalcoholic Fatty Liver and Drug-Induced Liver Diseases Model.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Coumarins; Cytochrome P-450 CYP2E1; | 2020 |
Fast food diet-induced non-alcoholic fatty liver disease exerts early protective effect against acetaminophen intoxication in mice.
Topics: Acetaminophen; Alanine Transaminase; Analgesics, Non-Narcotic; Animals; Chemical and Drug Induced Li | 2017 |
Acetaminophen aggravates fat accumulation in NAFLD by inhibiting autophagy via the AMPK/mTOR pathway.
Topics: Acetaminophen; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Autophagosomes; Autophagy; Bo | 2019 |
Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Bile Canaliculi; Biotransformation; Child; Coho | 2015 |
A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen.
Topics: Acetaminophen; Cell Line; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cytochrome P-450 | 2016 |
Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease.
Topics: Acetaminophen; Adolescent; Case-Control Studies; Child; Fatty Liver; Glucuronosyltransferase; Humans | 2011 |
Susceptibility of rat non-alcoholic fatty liver to the acute toxic effect of acetaminophen.
Topics: Acetaminophen; Animals; Biomarkers; Caspase 3; Chemical and Drug Induced Liver Injury; Cholesterol; | 2012 |
Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.
Topics: Acetaminophen; Biotransformation; Disease Progression; Fatty Liver; Gene Expression Regulation, Enzy | 2013 |